<DOC>
	<DOCNO>NCT03091712</DOCNO>
	<brief_summary>This open label randomize , control , parallel intervention study . Group 1 receive usual care insulin degludec titration use STEP WISE degludec titration algorithm Group 2 receive Glooko mobile insulin dose system , use STEP WISE degludec titration algorithm.An estimate n= 240 subject type 2 diabetes enrol order obtain approximately 200 evaluable subject complete 16 week study .</brief_summary>
	<brief_title>Insulin Degludec Titration Using Mobile Insulin Dosing System</brief_title>
	<detailed_description>This prospective randomize control two-group parallel design intervention trial . The primary endpoint , change baseline week 16 HbA1c plan test superiority Glooko Mobile Insulin Dosing System versus standard care insulin degludec titration - treatment Tresiba® U-200 FlexTouch® . An estimated n= 240 subject type 2 diabetes enrol order obtain approximately 200 evaluable subject complete 16 week study . The subject , already long-acting insulin insulin naïve subject start long-acting insulin degludec ( Tresiba® U-200 FlexTouch® ) . The subject randomize one two group : Group 1 receive standard care use STEP WISE degludec titration algorithm long act insulin titration . Group 2 receive standard care along treatment facilitate Glooko mobile insulin dose system , use STEP WISE degludec titration algorithm . Major study assessment conduct Baseline ( Screening &amp; Visit 1 ) , second Visit ( Visit 2 ) 12 week 3 month , 16 week 4 month , final set lab , meter download , subject survey administer ( Exit Labs Meter Download ) , addition , interaction subsequent care plan change complete HCP Unscheduled HCP Interactions document . Baseline , Visit 2 final screen/Exit Labs visit include : blood draw , body weight , questionnaire .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>1 . Subject ability sign inform consent form . Prior randomization patient sign information consent , approve Institutional Review Board/Independent Ethics Committee , provide Health Insurance Portability Accountability Act authorization ( HIPAA ) privacy authorization prior participation study . 2 . Subject 18 older document type 2 diabetes diagnosis least 3 month screen 3 . Subject HbA1c 7.5 % 12 % measure use NGSP certify method 4 . Subject BMI &lt; 40.0 5 . Subject initiate basal insulin therapy insulin degludec switch insulin degludec another basal insulin least 3 month and/or subject antihyperglycemic agent , include oral hypoglycemic ( OAs ) , noninsulin injectables ( e.g . GLP1 ) least 3 month . 6 . Subject male nonpregnant , nonlactating female , least 6 week postpartum prior screen visit . A urine pregnancy test require female subject unless childbearing potential , defined postmenopausal least one year prior screen visit surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) 7 . If female childbearing potential , practice one follow method birth control ( continue duration study ) : 1 . Condoms , sponge , diaphragm , intrauterine device ; 2 . Oral parenteral contraceptive 3 month prior screen visit ; 3 . Vasectomized partner ; 4 . Total abstinence sexual intercourse 8 . Subject Glooko compatible smartphone active data plan access WiFi download least one mobile application phone , 9 . Subject currently perform self monitor blood glucose ( SMBG ) 1 . Subject severe hypoglycemia episode last 90 day 2 . Subject type 1 diabetes 3 . Subject access Glooko compatible smartphone tablet 4 . Subject must use Glooko electronic application insulin titration 5 . Subject unable read understand English 6 . Subject use short act premixed insulin 10 day last 3 month 7 . Subject go initiate short act insulin prior study start 8 . Pregnant breastfeed woman , intention become pregnant use adequate contraceptive measure 9 . Visual impairment result inability see application . 10 . Use systemic steroid one week last 90 day screen 11 . Unable meet protocol requirement ( perform SMBG , administer insulin ) 12 . Known hypersensitivity / intolerance insulin degludec excipients 13 . Is participant another clinical study 14 . In opinion PI , subject already insulin properly manage long act insulin ( e.g. , introduction meal time insulin necessary ) 15 . Subject condition event consider exclusionary PI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Degludec</keyword>
	<keyword>MIDS</keyword>
	<keyword>Mobile Insulin Dosing System</keyword>
	<keyword>Glooko</keyword>
	<keyword>Tresiba</keyword>
	<keyword>Tresiba® U-200 FlexTouch®</keyword>
</DOC>